2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvivalReal‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal‐Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Medicine 2024, 13: e6953. PMID: 38348963, PMCID: PMC10832339, DOI: 10.1002/cam4.6953.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaRate of adverse eventsIncidence rate of adverse eventsAdverse eventsPatient-monthsLymphocytic leukemiaIncidence ratePatients treated with ibrutinibTreatment of chronic lymphocytic leukemiaStandard-of-care therapyNon-discontinuationInitiation of ibrutinibBTK inhibitor ibrutinibAdverse event ratesPotential side effectsInhibitor ibrutinibMedicare beneficiariesReal-world analysisAtrial fibrillationFollow-upIbrutinibSide effectsReal-world outcomesEvent ratesLeukemia
2021
First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
Park J, Winer E, Huntington S, von Keudell G, Vemuri S, Shukla M, Kinoshita J, Falco V, Gore S, Stone R, Abdel-Wahab O, Tallman M. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood 2021, 138: 43. DOI: 10.1182/blood-2021-151074.Peer-Reviewed Original ResearchHairy cell leukemiaAdverse eventsEfficacy of vemurafenibCR rateFebrile neutropeniaInfusion reactionsMonth 4Month 2Dose reductionDay 1Grand roundsResponse rateTreatment of HCLDrug-related adverse eventsMedian absolute CD4 countUntreated hairy cell leukemiaRefractory hairy cell leukemiaAdvisory CommitteeComplete response rateDurability of remissionGrade 1 feverMRD-negativity ratesMulti-center clinical trialSubsequent infusion reactionsAbsolute CD4 count
2020
Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma
Patel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsBest supportive careRefractory multiple myelomaMultiple myelomaSupportive careProbabilistic sensitivity analysesDisease progressionIncremental effectivenessIncremental costPost-progression therapyTwice-weekly bortezomibLarge randomized trialsProgression-free survivalUS payer perspectiveIncremental lifetime costOne-way sensitivity analysesCost-effectiveness ratioQuality of lifeCost of treatmentCost-effectiveness analysisVD progressionAnnual discount rateAdverse eventsHazard ratio
2019
Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimensAnti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Abrisqueta P, Sancho J, Cordoba R, Persky D, Andreadis C, Huntington S, Carpio C, Giles D, Wei X, Li Y, Zuraek M, Burgess M, Hege K, Martín A. Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood 2019, 134: 4089. DOI: 10.1182/blood-2019-125310.Peer-Reviewed Original ResearchIndependent data monitoring committeeCommon adverse eventsDose-limiting toxicityAdverse eventsCD47 antibodyData monitoring committeeSpeakers bureauR NHLFrequent grade 3/4 adverse eventsInternational Working Group response criteriaGrade 3/4 adverse eventsCelgene CorporationRefractory non-Hodgkin lymphomaBCR-ABL kinase domainAdvisory CommitteeMonitoring committeeF. Hoffmann-La Roche LtdDisease control ratePrior systemic therapyTreatment-related deathsDurable complete responseGrade 3 thrombocytopeniaInfusion-related reactionsModest clinical activityDose-limiting thrombocytopenia
2018
Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality
Huntington S, Schuster S, He W, Shen T, Walker H, Leary L, Boyhen K, Gill J, Chatburn E, Kennard K, Nasta S, Landsburg D, Porter D, Napier E, Hughes M, Latorre T, Walsh K, Dorsey C, Svoboda J, Addis V, Anderson B, Leblond E, Song Y, Zhu J, Deng L, Brander D, Ding W, Rosenthal A, Tun H, Mato A. Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. Blood 2018, 132: 5384. DOI: 10.1182/blood-2018-99-112944.Peer-Reviewed Original ResearchClassical Hodgkin lymphomaChronic lymphocytic leukemiaMantle cell lymphomaRefractory lymphoma patientsLow-dose combinationClinical trialsAdverse eventsFollicular lymphomaCancer HospitalLymphoma patientsStudy treatmentCell lymphomaDose combinationDose-limiting toxicity periodRefractory chronic lymphocytic leukemiaPeking University Cancer HospitalAdvisory CommitteeLarge B-cell lymphomaPhase Ia studyECOG performance statusSubsequent treatment cyclesBeijing Cancer HospitalMechanism-based combinationsB-cell lymphomaNovartis Pharmaceuticals Corporation